Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Zura Bio Ltd entered into License, Development and Commercialization Agreement with Eli Lilly and Company valued at upfront fee of $15,000,000 (effective 2023-04-26).
- Action
- entry
- Agreement
- license
- Counterparty
- Eli Lilly and Company
- Value
- upfront fee of $15,000,000
- Effective
- 2023-04-26
Exact text from the filing
Effective April 26, 2023, our subsidiary ZB17 LLC (“ZB17”) entered into a License, Development and Commercialization Agreement (the “License Agreement”) with Eli Lilly and Company (“Lilly”), pursuant to which Lilly granted to ZB17 an exclusive (even as to Lilly), payment-bearing license (the “Lilly License”) to develop, manufacture and commercialize a certain bispecific antibody relating to IL-17 and BAFF (“ZB-106”) in the field (meaning all uses including any and all human therapeutic, diagnosis, prevention, amelioration and prophylactic uses) worldwide.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Zura Bio Ltd entered into Subscription Agreements with certain individual and institutional accredited investors valued at approximately $80 million (effective 2023-04-26).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain individual and institutional accredited investors
- Value
- approximately $80 million
- Effective
- 2023-04-26
Exact text from the filing
On April 26, 2023, Zura Bio Limited (the “Company” or “Zura”) entered into certain subscription agreements (the “Subscription Agreements”) with certain individual and institutional accredited investors (the “Subscribers”) in connection with the sale by the Company (the “Private Placement”) of Class A ordinary shares, par value $0.0001 per share (the “Shares”) and pre-funded warrants (the “Pre-Funded Warrants”)
View on SEC.gov